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Abstract
Background:  Pseudomonas aeruginosa and Burkholderia cepacia infections of cystic fibrosis
patients' lungs are often resistant to conventional antibiotic therapy. Protegrins are antimicrobial
peptides with potent activity against many bacteria, including P. aeruginosa. The present study
evaluates the correlation between protegrin-1 (PG-1) sensitivity/resistance and protegrin binding in P.
aeruginosa and B. cepacia.
Methods:  The PG-1 sensitivity/resistance and PG-1 binding properties of P. aeruginosa and B.
cepacia were assessed using radial diffusion assays, radioiodinated PG-1, and surface plasmon
resonance (BiaCore).
Results: The six P. aeruginosa strains examined were very sensitive to PG-1, exhibiting minimal active
concentrations from 0.0625–0.5 µg/ml in radial diffusion assays. In contrast, all five B. cepacia strains
examined were greater than 10-fold to 100-fold more resistant, with minimal active concentrations
ranging from 6–10 µg/ml. When incubated with a radioiodinated variant of PG-1, a sensitive P.
aeruginosa strain bound considerably more protegrin molecules per cell than a resistant B. cepacia
strain. Binding/diffusion and surface plasmon resonance assays revealed that isolated
lipopolysaccharide (LPS) and lipid A from the sensitive P. aeruginosa strains bound PG-1 more
effectively than LPS and lipid A from resistant B. cepacia strains.
Conclusion:  These findings support the hypothesis that the relative resistance of B. cepacia to
protegrin is due to a reduced number of PG-1 binding sites on the lipid A moiety of its LPS.
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Introduction
Cystic fibrosis (CF) is a generalized exocrine disease re-
sulting from the defective regulation of epithelial chloride
ion transport within various organ systems, most important-
ly the lungs [1–4]. This dysfunction can arise from a variety
of mutations within the cystic fibrosis transmembrane con-
ductance regulator (CFTR) gene on chromosome 7, which
encodes the transmembrane pump responsible for regulat-
ing transepithelial ion levels [1,2,4]. This defect is associat-
ed with an increased viscosity of the airway surface fluid,
and according to some studies, an altered salt concentra-
tion [5,6]. These and other pleiotropic effects of the CF
gene abnormality increase the susceptibility of CF patients
to bronchopulmonary bacterial infection by opportunistic
pathogens.
Pseudomonas aeruginosa is the most common pathogen
recovered from the lungs of CF patients [2,3]. This predis-
position to P. aeruginosa infection has been attributed to
several factors. For example, an increase in asialo-GM1
glycoproteins on the apical surface of CF airway epithelial
cells provides greater opportunity for adhesion by the type
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IV pili of P. aeruginosa[3,7,8]. Furthermore, the first extra-
cellular domain of wild type CFTR has been found to act as
a P. aeruginosa-specific receptor, which is involved in the
clearance of P. aeruginosa from the airways via epithelial
cell desquamation [9–11], a process greatly impaired in
the CF lung. Other conditions that abet colonization of the
CF lung include impairment of the "mucociliary escalator"
and macrophage-mediated phagocytosis by the viscous
airway secretions. If elevated salt concentrations exist with-
in these secretions [5,6], they would inhibit α  and β -de-
fensins, endogenous antibacterial peptides produced by
neutrophils and airway epithelia, respectively [2,3,12–15].
This last point is still under review as recent evidence sug-
gests that CF airway surface fluid may be isotonic not
hypertonic [16].
In recent years Burkholderia cepacia has become the sec-
ond leading cause of death in patients with chronic granu-
lomatous disease (CGD). The phagocytes of such patients
are deficient in their capacity to kill organisms by oxidative
means because of a defective NADPH oxidase [17,18]. B.
cepacia also poses a threat to patients with CF, either co-
colonizing those already infected with P. aeruginosa or as
the sole infecting agent [2,18]. Although rates of coloniza-
tion can vary widely (between 5 and 70%), B. cepacia is
isolated from sputum in only 10%–20% of patients with CF
[2,3]. B. cepacia, a very diverse species, has been divided
into several "classes" of bacteria, i.e., genomovars, collec-
tively referred to as the B. cepacia complex. Genomovar III
is the most common B. cepacia genomovar isolated from
CF patients, accounting for approximately 80% of B. cepa-
cia isolates in CF patients. Genomovars II and V have also
been recovered from CF patients [18]. Of critical concern
are B. cepacia's transmissibility from one patient to another
and its propensity to give rise to the B. cepacia syndrome,
which results in a rapid decline in pulmonary function
[2,18]. The ability of B. cepacia as well as P. aeruginosa to
cause chronic bronchopulmonary infections in CF patients
is exacerbated by their intrinsic or acquired resistance to
many conventional antibiotics. Peptide antibiotics, includ-
ing protegrins, are currently under consideration as novel
agents for treating pulmonary infections in CF patients.
Antimicrobial peptides are synthesized either nonribosoma-
lly or ribosomally [19]. Protegrin-1 (PG-1), a 2 kDa cationic
octadecapeptide (RGGRLCYCRRRFCVCVGR-amide)
was originally isolated from porcine leukocytes [20] and
falls into the latter category. We selected it for this study
because it is rapidly bactericidal, functions well at elevated
physiological salt concentrations such as those that may
occur in the CF lung, and has a broad spectrum of activity
[21–23]. PG-1's antiparallel β -hairpin structure and antimi-
crobial activity in physiological and elevated salt concentra-
tions are maintained by its two intramolecular cystine
disulfide bonds [21,24–28]. The antimicrobial spectrum of
PG-1 includes Chlamydia trachomatis, Candida albicans,
Escherichia coli, Fusobacterium nucleatum, Haemophilus
ducreyi, Listeria monocytogenes, Neisseria gonorrhoeae,
Porphyromonas gingivalis, Prevotella intermedia, P. aeru-
ginosa, and Staphylococcus aureus[20,22,25,29–32].
This study tested the hypothesis that the relative sensitivity
or resistance of P. aeruginosa and B. cepacia strains to
PG-1 correlates to the extent of peptide binding. A previ-
ously described two-stage radial diffusion technique de-
signed for peptide antibiotics was used to determine
susceptibility. Binding of protegrins to intact P. aeruginosa
and  B. cepacia cells and to purified lipopolysaccharide
(LPS) and lipid A prepared from these organisms was
measured by three different techniques.
Materials and methods
Bacterial strains and growth media
Two sets of genetically related P. aeruginosa strains were
studied. Strain 144M, a serum-sensitive mucoid isolate
from a CF patient, contains short O-side chain LPS, while
its serum-resistant derivative, 144M(SR), which is also mu-
coid, has long O-side chain LPS [33]. Strain FRD-1 is a mu-
coid CF isolate [34] and FRD-2 is its spontaneous
nonmucoid derivative [35]. P. aeruginosa ATCC strains
10145 and 9027 are nonmucoid strains with long O-side
chain LPSs [N L Schiller, unpublished results]. We also
studied B. cepacia ATCC strains 25416 and 25609, as
well as three clinical strains isolated from patients with CF
in Vancouver, Canada, kindly provided by David P Speert,
University of British Columbia. These strains included:
C4813, genomovar IIIa, B. cepacia epidemic strain marker
(BCESM) positive, cable pilin subunit gene A (cable A)
negative; C4878, genomovar IIIa, BCESM positive, cable A
negative; and C6159, genomovar IIIb, BCESM and cable A
negative. BCESM and cable A are putative transmissibility
markers [36]. Log-phase cultures were grown at 37°C with
shaking in trypticase soy broth (TSB) (Becton-Dickinson
Microbiology, Cockeysville, MD).
Protegrin
PG-1 was prepared as previously described [25] and was
approximately 96.5% pure. PG-1 was dissolved in and di-
luted with filter-sterilized acidified water (0.01% acetic ac-
id) supplemented with 0.1% human serum albumin (Sigma,
St. Louis, MO). The albumin in the PG-1 vehicle helped re-
duce nonspecific adsorption of protegrins when the stock
solutions were serially diluted [22,37]. These PG-1 stock
solutions were filter-sterilized prior to storage at either
-20°C for short term (<3 months) or -80°C for long-term
storage.
Radial diffusion assay
The two-stage radial diffusion assay protocol as described
by Steinberg and Lehrer [37] and Lehrer et al. [38] was al-Available online http://respiratory-research/content/3/1/18
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tered by supplementing the underlay agar with 150 mM
NaCl to ascertain PG-1's ability to kill P. aeruginosa and B.
cepacia at an elevated salt concentration. These assays
were interpreted as described below. The sample wells re-
ceived 5 µl of PG-1 (various concentrations) or its vehicle.
We analyzed the radial diffusion assay results in two ways.
In one, we calculated the lethal concentration (CL) as de-
scribed by Hultmark et al. [39,40] from wells surrounded by
net clear zones of 1 to 2.5 mm. In the other, we defined the
minimal active concentration (MAC) as the lowest concen-
tration of PG-1 that produced a measurable, totally clear,
inhibition zone around the well.
Whole cell binding assay
Binding of PG-1 to intact cells was measured with a mono-
radioiodinated variant of PG-1. This protegrin variant dif-
fered from PG-1 in two ways: Phe7 replaced Tyr7 in the
protegrin domain, and an N-terminal glycine-rich hexapep-
tide extension (GGGYGG) with a single tyrosine residue
was present. In this report the modified peptide and its mo-
noiodinated variant will be called "GGPG" and "I-GGPG",
respectively. The full sequence of GGPG is GGGYGGRG-
GRLCFCRRRFCVCVGR-CONH2. In preliminary experi-
ments, we determined that PG-1, GGPG, and I-GGPG
exhibited virtually identical antimicrobial potency and kinet-
ics (data not shown).
GGPG was iodinated with NaI or Na125I (Pierce, Rockford,
IL) by the iodobead method [41,42]. Unincorporated NaI or
Na125I was removed by solid phase extraction on a Sep-
Pak C-18 Plus Cartridge. I-GGPG was purified from unio-
dinated and di-iodinated GGPG by reverse phase-HPLC
(Vydac, Hesperia, CA). Binding assays were done with sta-
tionary phase P. aeruginosa 9027 or B. cepacia 25416,
both typically at 2.5 ×  107 CFU/ml. The bacteria were incu-
bated with 125I-GGPG at 0° C for 60 min at pH 7.4 in a 10
mM Tris-acetate buffer containing 100 mM NaCl, 1% TSB,
and 1% BSA. Samples were layered over 0.3 ml of a cush-
ion composed of 5 parts of dibutyl phthalate and 3 parts of
di-isodecyl phthalate (density20 = 1.01) and centrifuged at
approximately 14,000 ×  g. After removing the supernatant
and phthalate oil, the base of the tube was severed with a
razor blade and the stub, which contained the pellet, was
recovered for radioactivity counting.
LPS and lipid A extraction and analysis
Bacterial LPS was isolated according to the protocol of
Darveau and Hancock [43] with some modifications, as de-
scribed below. Strains were grown overnight in TSB, col-
lected via centrifugation (10,000 ×  g for 20 min at 0°C),
and suspended in a pH 8.0 buffer (5.0 g of wet weight bac-
teria/30 ml of buffer) that contained 10 mM Tris-hydrochlo-
ride, 2 mM MgCl2, 100 µg/ml DNase I, and 25 µg/ml
RNase I. The slurry was passed twice through a French
Press set at 20,000 lbs/in2. DNase and RNase were again
added, and the mixture was incubated at 37°C for 2 hours.
Then, to each 15 ml of suspension, the following were add-
ed: 5.0 ml of 0.5 M tetrasodium EDTA in 10 mM Tris buffer,
2.5 ml of 20% SDS in 10 mM Tris buffer, and 2.5 ml of 10
mM Tris buffer. The preparation was mixed and centrifuged
at 50,000 ×  g for 30 min at 20°C to remove the peptidog-
lycan. Protease (Sigma P5147) at 200 µg/ml was added to
the supernatant and incubated at 37°C overnight with agi-
tation. On the next day, 0.375 M MgCl2 in 95% ethanol
was added and the suspension was cooled to 0°C before
centrifugation at 12,000 ×  g for 15 min at 0°C. The result-
ing pellet was resuspended in 2% SDS, 0.1 M tetrasodium
EDTA in 10 mM Tris buffer and sonicated. This solution
was incubated at 85°C for 30 min, and cooled to room tem-
perature before protease (25 µg/ml) was added and incu-
bated overnight at 37°C. After re-precipitation the following
day with ethanol, the pellet was resuspended in 10 mM Tris
buffer and centrifuged at 200,000 ×  g for 2 hours at 20°C
in the presence of 25 mM MgCl2. The final LPS extract was
suspended in 10 ml dH2O and dialyzed overnight against
dH2O to remove any residual salt and SDS prior to being
lyophilized. Contamination of the LPS samples by protein
represented no more than 3.6% ± 0.21%, as estimated by
measuring the dry weight and protein concentration with
the Bio-Rad Protein Assay Kit. Nucleic acid contamination
was considered to be minimal due to the repeated DNase
and RNase treatments. LPS preparations were diluted us-
ing the PG-1 vehicle prior to assaying with PG-1.
Lipid A was extracted from isolated LPS preparations via
acid hydrolysis [44,45]. Isolated LPS (25–30 mg) was sus-
pended in 4 ml of a 1% acetic acid solution and heated in
a water bath to 100°C under refluxing conditions for 3
hours. Once the lipid A was hydrolyzed, it precipitated out
of solution and was extracted with five sequential 4 ml aliq-
uots of chloroform. Lipid A extracts were collected and
washed three times with 10 ml aliquots of dH2O before be-
ing lyophilized. Lipid A was dissolved in 100% dimethyl sul-
foxide (DMSO), which was diluted to 2.5% with the PG-1
vehicle before application in the radial diffusion assay.
In order to measure the ability of LPS and lipid A to bind
PG-1, we modified the two stage radial diffusion assay so
that we could ascertain the amount of LPS or lipid A (in ng),
that reduced the antimicrobial activity of 50 ng of PG-1 by
50 percent (called the effective concentration 50% or
EC50). Briefly, 2.5 µl of a 20 µg/ml PG-1 solution and 2.5
µl of LPS or lipid A (at various concentrations based on
their dry weight) were combined, and added to the radial
diffusion wells. After a 3-hour incubation, a nutrient rich
overlay gel was poured and the plates were incubated over-
night. The following day, zone diameters (including the
wells) were measured in mm. Since the height (h) of the un-
derlay gel was always 1.2 mm, the zone diameters were
converted to volumes cleared of viable bacteria with the for-Respiratory Research   Vol 3 No 1    Albrecht et al
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mula for the volume of a cylinder: V=π  r2h. Since the 3 mm
diameter sample well was devoid of both bacteria and pep-
tide, its volume (8.5 µl) was subtracted from the gross clear
zone volume (π  r2h) to derive the net volume rendered free
of bacteria. As will be shown below, this net volume was a
linear function of the amount of PG-1 placed in the well, for
amounts of protegrin between 0–50 ng/ well.
Surface plasmon resonance
Binding of LPS or lipid A to PG-1 was assessed with a Bi-
acore 2000 system (BiaCore AB, Piscataway, NJ); a very
similar approach was used to study LPS binding by peptide
domains of horseshoe crab factor C [46]. This innovative
technology uses surface plasmon resonance to study bio-
molecular interactions in real time. Briefly, the binding takes
place on a small chip coated with a thin layer of metal. It is
monitored by monochromatic, p-polarized light whose elec-
tric vector component is parallel to the plane of incidence.
Under these conditions, the intensity of the reflected light is
markedly reduced at a specific incident angle, producing a
sharp "shadow". This phenomenon is called "surface plas-
mon resonance" (SPR) and the incident light angle at
which the shadow is observed is the "SPR angle". Detec-
tion of the SPR angle depends on changes in the refractive
index (RI) of the medium on the nonilluminated side of the
chip. Since this RI depends on the mass concentration of
macromolecules at this surface, monitoring the SPR angle
provides a real-time measure of changes in the surface
concentration. The SPR spectrum is a plot of the SPR an-
gle against time, and displays the interaction's progress at
the sensor surface. The SPR signal is expressed in reso-
nance units (RU), and 1000 RU is equivalent to a change
in surface protein concentration of about 1 ng/mm2 or of
about 6 mg/ml in the bulk protein concentration.
In our study, LPS and lipid A samples from P. aeruginosa
9027 and B. cepacia 25416 were immobilized on a hydro-
phobic HPA sensor chip (BR-1000–30, Biacore AB) that
was found, in our preliminary experiments, to provide an op-
timal matrix for LPS and lipid A. The surface of HPA sensor
chips is composed of long-chain alkanethiol molecules that
form a flat, quasi-crystalline hydrophobic layer that facili-
tates hydrophobic adsorption of liposomes or micelles on a
user-defined polar lipid monolayer. The chip was pre-
cleaned and conditioned by washing twice with 40 mM n-
octyl glucoside (Sigma Chemical Co.). To immobilize the
LPS, 60 µl of a 1 mg/ml LPS preparation was dispersed in
100 mM NaCl containing 10 mM HEPES buffer (pH 7.4),
and passed across the chip's surface for 30 min, at flow
rate of 2 µl/min. Lipid A was dissolved and immobilized sim-
ilarly, except that its concentration was reduced to 0.2 mg/
ml. Residual unbound LPS and lipid A were washed away
with 0.1 M HCl and 0.1 M NaOH. BSA (0.1 mg/ml) was
used to detect nonspecific binding on the surfaces coated
by LPS or lipid A. PG-1 binding was measured by observ-
ing the change in the SPR angle of the sample bound to the
chip as 30 µl of PG-1 (20 µM, 10 µM, 6 µM, 3 µM, 2 µM,
and 1 µM) flowed over the sample for 3 min at a rate of 10
µl/min. These PG-1 solutions were also prepared in 100
mM NaCl containing 10 mM HEPES buffer (pH 7.4). Each
binding study was done in triplicate and the chip was re-
generated between trials by washing it with 0.1 M HCl and
0.1 M NaOH.
Results
Activity of PG-1 on P. aeruginosa and B. cepacia strains
The CL and MAC for PG-1 on P. aeruginosa and B. cepa-
cia were determined in two-stage radial diffusion assays
(Table 1). The mean CL of PG-1 for the six P. aeruginosa
strains was 0.30 µg/ml, and the mean CL for the five B. ce-
pacia strains was 5.02 µg/ml, a 16.7-fold difference. The
mean MACs for P. aeruginosa and B. cepacia were 0.17
µg/ml and 8.40 µg/ml, respectively. The CL and MAC val-
ues for P. aeruginosa and B. cepacia differed significantly
(P exact = 0.004) when the data were analyzed by the
Mann-Whitney test.
We also compared two sets of genetically related P. aeru-
ginosa strains: 144M/144M(SR) and FRD-1/FRD-2.
Whereas the LPS of strain 144M has a very short O-anti-
gen side chain, LPS from strain 144M(SR) has a very long
O-antigen side chain. However, despite these differences
both strains had comparable CL and MAC values. Similarly,
comparison of the alginate producer FRD-1 with FRD-2, its
spontaneous nonmucoid derivative, revealed that both
strains had very similar CL and MAC values.
Intact/whole cell binding
Incubation of 125I-GGPG with intact P. aeruginosa 9027
(PG-1 sensitive) and B. cepacia 25416 (PG-1 resistant)
cells demonstrated a marked difference in protegrin bind-
ing between the two strains (Fig. 1). When the bacteria
were exposed to 12.5 µg 125I-GGPG /ml, approximately
sixfold more protegrin molecules bound to P. aeruginosa
than to B. cepacia, and at an 125I-GGPG concentration of
25 µg/ml, 12 times as many protegrin molecules bound to
P. aeruginosa. Another factor also merits mention in this re-
gard. By light microscopy, the B. cepacia cells appeared
larger than the P. aeruginosa cells. By electron microscopy,
we found that the mean cross sectional diameters and
lengths of B. cepacia 25416 cells were 0.755 µm ×  2.55
µm. The corresponding values for P. aeruginosa 9027 cells
were 0.615 µm ×  2.35 µm. Assuming a cylindrical structure
for both, we calculated that the surface area of the B. ce-
pacia cells (6.00 µm2) was approximately 33% larger on
average than that of P. aeruginosa (4.54 µm2).
Binding of PG-1 to LPS and lipid A
To compare binding of PG-1 to LPS and lipid A from P. aer-
uginosa 9027 and B. cepacia 25416, we devised a simpleAvailable online http://respiratory-research/content/3/1/18
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Table 1
CL and MAC values for various P. aeruginosa and B. cepacia strains determined using the radial diffusion assay.
Organism Strain Comments CL
* MAC*
P. aeruginosa 144M Serum sensitive, mucoid, short chain LPS 0.20 0.0625
P. aeruginosa 144M (SR) Serum resistant, mucoid, long chain LPS 0.18 0.0625
P. aeruginosa FRD-1 Mucoid strain 0.15 0.125
P. aeruginosa FRD-2 Nonmucoid strain 0.19 0.125
P. aeruginosa 10145 ATCC strain 0.25 0.125
P. aeruginosa 9027 ATCC strain 0.81 0.50
Mean ± SEM (all 6 strains) 0.30 ± 0.10** 0.17 ± 0.07**
B. cepacia C6159 Clinical isolate 1.35 6
B. cepacia C4813 Clinical isolate 5.70 8
B. cepacia C4878 Clinical isolate 1.53 8
B. cepacia 25416 ATCC strain 7.57 10
B. cepacia 25609 ATCC strain 8.95 10
Mean ± SEM (all 5 strains) 5.02 ± 1.55** 8.40 ± 0.75**
*Each value represents the mean of three replicate assays, shown in µg/ml. **Mann-Whitney test, P. aeruginosa versus B. cepacia, P exact for CL = 
0.004, MAC = 0.004.
Figure 1
Binding of 125I-GGPG. Stationary phase bacteria, 2.5 ×  107 CFU/ml, were incubated with the indicated concentrations of I125-GGPG for 60 min at
0 °C, and centrifuged through a phthalate ester "cushion" to separate free and bound peptides. The data points are mean ± SEM values from 5 to 9
replicates obtained in three separate experiments. Using the Mann-Whitney test, P was < 0.05 at values indicated by **.
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bioassay based on the radial diffusion assay. As shown in
Fig. 2, for protegrin amounts between 0 and 50 ng, the vol-
ume of underlay gel that was rendered completely free of
viable bacteria was linearly related to the amount of peptide
introduced into the well. By mixing a constant amount of
protegrin (within this linear range) with graded amounts of
purified LPS and lipid A, we could readily determine how
much of these ligands were needed to reduce the activity
of 50 ng of PG-1 by 50% (the EC50 values). The results of
our assays with LPS and lipid A purified from the strains we
used in the above 125I-GGPG binding studies are shown in
Fig. 3A. The EC50 values for LPS isolated from P. aerugi-
nosa and B. cepacia differed by 4.6-fold (100 ng versus
460 ng) while the EC50 values for lipid A isolated from the
same strains differed by approximately 16.7-fold (60 ng
versus 1000 ng).
To ascertain if these findings were representative, we pre-
pared LPS and lipid A from another pair of bacteria (P. aer-
uginosa FRD-2 and B. cepacia C4813) and repeated the
studies. The EC50 values for both LPS and lipid A obtained
from P. aeruginosa FRD-2 were each 120 ng. The values
for B. cepacia LPS and lipid A were estimated as approxi-
mately 2050 ng for both (Fig. 3B), a difference of 17.1-fold
when compared to P. aeruginosa FRD-2 LPS and lipid A.
Surface plasmon resonance studies
We also used SPR spectroscopy to compare the binding
of PG-1 to LPS and lipid A purified from P. aeruginosa
9027 and B. cepacia 25416. Injection of LPS or lipid A
from both strains was stopped when the increase in RU of
both reached 1000. Loosely bound molecules were
washed away by increasing the flow rate to 100 µl/min, fol-
lowed by two, one-minute short pulse injections of 100 mM
NaOH. Injections of 0.1 mg/ml BSA prepared in the eluent
buffer were passed across the LPS or lipid A coated sur-
faces for a five-minute period and showed an increase of
around 100 RU, whereas the same amount of BSA passed
Figure 2
Quantitative aspects of PG-1 mediated killing measured by two-stage radial diffusion assays. The left ordinate scale shows the net area of underlay
gel totally cleared of viable bacteria using the equation (π  d2-9)÷ 4, where d is the diameter of the cleared zone including the well diameter and 9 is
subtracted to account for the area of the well, which is devoid of bacteria. The right ordinate scale shows the volume cleared (area cleared times the
height of the underlay gel, 1.2 mm). All data points are means (n = 3). Note that Y is a linear function of X for these peptide concentrations. Area (A)
and volume (V) are related by the equation: A (mm2) = V (µl)/1.2 mm.
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across the uncoated, n-octyl glucoside washed surface
showed an increase of roughly 1000 RU. This demonstrat-
ed that the surface of the chip was fully covered by LPS or
lipid A. Since similar amounts of these ligands had bound
to the chip, the response unit differences seen at concen-
trations between 1 and 20 µM indicate that approximately
twice as much PG-1 bound P. aeruginosa lipid A as bound
lipid A from the B. cepacia strain (Fig. 4). Binding differenc-
es were less marked when we studied LPS from these or-
ganisms (Fig. 5). Although up to one third more protegrin
molecules bound to P. aeruginosa LPS than to B. cepacia
LPS at protegrin concentrations of 1–6 µM, these differ-
ences disappeared when we tested higher PG-1 concen-
trations. At 10 µM PG-1, LPS from P. aeruginosa and B.
cepacia bound PG-1 equally ( 750 response units). Equal
binding was also seen at 20 µM PG-1 ( 1000 response
units).
Discussion
In this study we compared the sensitivity of P. aeruginosa
and B. cepacia strains to protegrin PG-1 with the ability of
the intact bacteria and key components of their outer mem-
branes (LPS and lipid A) to bind this peptide. The indices
of susceptibility (CL and MAC values) obtained from our ra-
dial diffusion assays established that P. aeruginosa was
considerably more sensitive to PG-1 than B. cepacia. We
also found that at any given peptide concentration, many
fewer protegrin molecules bound to intact B. cepacia and
its lipid A than to the corresponding P. aeruginosa prepa-
rations. In model systems, the ability of protegrins to perme-
abilize membranes shows pronounced "concentration-
gating", an indication that it is influenced by the density of
bound protegrin molecules per unit area of membrane [47].
As prior quantitative studies of peptide binding are few in
number, some readers may be surprised to note that Fig. 1
shows many millions of protegrin molecules are bound to
an average bacterial cell, even at concentrations around the
minimal active concentration. To acquire an equivalent den-
sity of surface-bound PG-1 molecules, B. cepacia needed
exposure to much higher concentrations of PG-1 than P.
aeruginosa. Thus, it is a reasonable inference that the rela-
tive resistance of B. cepacia to PG-1 is a consequence of
Figure 3
Binding of PG-1 to LPS and lipid A. Binding/radial diffusion assays were conducted by mixing various amounts of LPS or lipid A with 50 ng of PG-1
in a final volume of 5 µl. In Panel A, the LPS and lipid A preparations were isolated from P. aeruginosa strain 9027 and B. cepacia strain 25416. In
Panel B, the LPS and lipid A were isolated from P. aeruginosa FRD-2 and B. cepacia C4813. The mixtures of PG-1 with LPS or lipid A were intro-
duced into the wells of radial diffusion assay plates seeded with P. aeruginosa FRD-1, a highly susceptible test organism. All data points are means
(n = 3), and EC50 values were extrapolated from these graphs. When these binding isotherms were subjected to linear regression analysis, the 95%
confidence limits of the LPS and lipid A binding isotherms for P. aeruginosa and B. cepacia were non-overlapping, and the isotherms for the LPS
preparations in Panel A overlapped only at the lowest ligand concentrations (data not shown).Respiratory Research   Vol 3 No 1    Albrecht et al
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the smaller number of protegrin molecules bound per unit
area of bacterial surface.
Earlier studies have shown that certain structural differenc-
es in the LPS of Gram-negative bacteria correlate with their
susceptibility or resistance to antimicrobial (lipo)peptides
[19,23,48–51]. Particular attention has been given to alter-
ations of the outer membrane that could modify binding to
the cell surface. For example, sensitivity to the antibacterial
lipopeptide polymyxin B is affected by the PmrA-PmrB reg-
ulon, which mediates substitution of 4-aminoarabinose on
the 4´ phosphate of lipid A [52,53]. By reducing the nega-
tive charge of lipid A, this modification decreases its elec-
trostatic interaction with cationic peptides. Resistance to
polymyxin B is also imparted by the absence or masking of
critical binding sites required for polycation-mediated per-
meabilization of the outer membrane [54]. Thus, attach-
ment of polymyxin B to Yersinia enterocolitica is reduced by
steric hindrance generated by the size and/or branched
shape of the outer core region of its LPS macromolecule
[55]. Additionally, resistance to cationic peptides can be
due to cytoplasmic clearance of the antimicrobial peptide
by an efflux pump; e.g., Yersinia resistance to polymyxin B
caused by the RosA/RosB efflux pump/potassium antiport-
er [56] and Neisseria gonorrhoeae resistance to protegrin
PG-1 via an energy-dependent efflux system termed mtr
[57].
Given the notorious resistance of B. cepacia to convention-
al antibiotics [2], its relative resistance to PG-1 was not un-
expected. What bacterial properties influenced sensitivity
to protegrins? Certainly, the striking correlation with the ex-
tent of protegrin binding must be one of these. Our studies
with genetically related P. aeruginosa strains did not impli-
cate the length of the O-antigen side chain as a key factor.
Furthermore, genetically related P. aeruginosa strains that
differed in alginate production were equally sensitive to
PG-1. Both results were somewhat surprising, since long
O-side chain and alginate molecules should both bind PG-
1. Perhaps limited alginate production under our experi-
Figure 4
Surface plasmon resonance (SPR) studies of isolated lipid A. PG-1 binding was measured by observing the change in the SPR angle of the sample
bound to the chip (P. aeruginosa 9027 lipid A in the left panel, B. cepacia 25416 lipid A in the right panel) as 30 µl of PG-1 at the indicated concen-
trations (1 to 20 µM) flowed over the sample. All data points are means (n = 3).
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mental conditions explains its failure to influence suscepti-
bility to PG-1. Additional studies focusing on the influence
of alginate on PG-1 activity in a biofilm model are in
progress.
Why did fewer protegrin molecules bind to B. cepacia than
to P. aeruginosa? Our radial diffusion/binding and SPR
studies strongly implicated lipid A as a prime suspect in the
case. The acyl chains of lipid A form an integral part of the
outer membrane bilayer, and electrostatic or hydrophobic
binding of protegrin to lipid A could easily disturb the or-
ganization and acyl-chain packing of the outer membrane,
both vital in maintaining its integrity and barrier function. Ac-
cepting a direct proportionality between measured plas-
mon resonance (RU) and the extent of peptide bound to the
sensor surface, the responses shown in Fig. 4 indicate that
at saturation (20 µM), lipid A from B. cepacia bound almost
exactly one-half as many protegrin molecules as lipid A from
P. aeruginosa. How might this be rationalized?
Lipid A typically contains two phosphate groups, one on
each glucosamine residue. In the lipid A of B. cepacia, one
of these phosphates is modified by a phosphodiester-
linked 4-amino-4-deoxyarabinose residue [58,59]. It is
noteworthy that a previous study reported that the phos-
phate content of B. cepacia LPS was only one-third of that
of P. aeruginosa[60]. If most of the P. aeruginosa lipid A
phosphates are unmodified, and if these phosphates are
principal protegrin binding sites, then one would expect ex-
actly the results shown in Fig. 4. This is also consistent with
the suggestion, made in a recent report showing that cystic
fibrosis isolates of P. aeruginosa had lipid A isoforms deri-
vatized with aminoarabinose (or palmitate), that these
structural modifications could enhance resistance to cati-
onic antimicrobial peptides [61]. Although the acyl chains
of lipid A might also provide alternative binding sites for
protegrin, the orientation of lipid A on the HPA sensor chip
("butter-side down") probably removes them from consid-
eration, at least under our study conditions.
The core and outer polysaccharide regions of LPS should
provide additional binding sites, including the carboxylate
moieties of KDO or KO (D-glycero-D-talo-oct-2-ulopyrano-
sylonic acid [62]. This could explain why B. cepacia LPS
Figure 5
Surface plasmon resonance (SPR) binding studies of isolated LPS. PG-1 binding was measured by observing the change in the SPR angle of the
sample bound to the chip (P. aeruginosa 9027 LPS in the left panel, B. cepacia 25416 LPS in the right panel) as 30 µl of PG-1 at the indicated con-
centrations (1 to 20 µM) flowed over the sample. All data points are means (n = 3).
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binds about as much PG-1 as P. aeruginosa LPS (Fig. 5)
especially at peptide concentrations of 10–20 µM, which
allow binding to lower affinity sites. This interpretation helps
explain why Fig. 3 suggests that B. cepacia LPS binds pro-
tegrin less effectively than the corresponding P. aeruginosa
preparation, while the SPR results in Fig. 5 show that B. ce-
pacia and P. aeruginosa LPS bound equivalent amounts of
PG-1 at high (10–20 µM) protegrin concentrations. To re-
solve these seemingly discrepant results, it is important to
recall that in SPR assays, the sensor chips were constantly
bathed with a fixed protegrin concentration ranging from 1–
20 µM and that in radial diffusion assays, the wells received
a fixed initial amount of protegrin (50 ng). In the latter as-
says, the peptide was dispersed in a total volume of 10 µl,
making its maximal initial concentration approximately
2.3µM – well below the 10–20 µM concentrations needed
to saturate LPS. Moreover, in addition to binding the LPS
or lipid A molecules we added to the well, some of the ini-
tially added protegrin could diffuse radially into the underlay
gel. Both initial binding and radial diffusion will decrease
the concentration of free (i.e., unbound) protegrin that re-
mains in the well, and further skew its binding towards high-
er affinity binding sites on lipid A.
Although our data clearly establish the presence of a re-
duced number of binding sites for protegrin in lipid A from
B. cepacia, as compared to lipid A from P. aeruginosa, they
do not identify the cause of this phenomenon. These alter-
ations could result from 4-aminoarabinose substitutions on
the lipid A, from other changes that reduce the number of
ion-binding sites, or from changes that affect hydrophobic
interactions or membrane insertion. Additional studies that
characterize B. cepacia LPS and lipid A can help pinpoint
the exact structural differences that relate to the relative re-
sistance of B. cepacia to protegrins and to endogenous an-
timicrobial peptides of humans.
Conclusion
Our studies demonstrate a correlation between protegrin
sensitivity/resistance and protegrin binding in P. aerugino-
sa and B. cepacia, and support a hypothesis that the rela-
tive resistance of B. cepacia to protegrin is due principally
to a reduced number of protegrin binding sites on the lipid
A moiety of its LPS.
Abbreviations
BSA = bovine serum albumin; CF = cystic fibrosis; CFTR = cystic fibro-
sis transmembrane conductance regulator; CL = lethal concentration;
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